Date: 2017-05-08
Type of information: Private placement
Company: Argen-X (Belgium - The Netherlands)
Investors:
Amount:
Funding type: private placement
Planned used:
Others:
- • On May 8, 2017, argenx announced that it intends to offer and sell, subject to market and other conditions, 3.6 million American Depositary Shares representing 3.6 million ordinary shares in an initial public offering in the United States. The final issuance price per ADS sold in the Offering will be determined following the bookbuilding process. Each of the ADSs offered in the Offering represents the right to receive one ordinary share.
- argenx intends to grant the underwriters of the Offering a 30-day option to purchase additional ordinary shares in the form of ADSs, provided that the number of such additional ADSs shall not exceed 15% of the ADSs sold in the Offering.
- argenx's ordinary shares are currently listed on the regulated market of Euronext Brussels. argenx has made an application to have its ADSs listed on the NASDAQ Stock Market under the symbol "ARGX". Application will also be made to admit the ordinary shares issued pursuant to the Offering to trading on the regulated market of Euronext Brussels.
- Cowen and Company and Piper Jaffray & Co. are acting as joint bookrunning managers for the Offering, and JMP Securities and Wedbush PacGrow are acting as co-managers. Kempen & Co is acting as argenx's advisor in connection with the Offering.
Therapeutic area:
Is general: Yes
